23 August,2021 06:58 PM IST | New Delhi | PTI
Photo for representational purpose
People who participated in Covid-19 vaccine trials will be issued digital certificates through the Co-WIN portal, the Union health ministry said on Monday.
In a statement, the ministry said it received several requests from trial participants for issuing certificates through Co-WIN.
"In a welcome initiative, digital #COVID19 vaccination certificates will now be issued to the clinical trial participants of COVISHIELD & COVAXIN through Co-WIN. The nation thanks them for their incredible commitment & contribution to COVID-19 vaccine research & treatment," Union Health Minister Mansukh Mandaviya tweeted.
"The participants can download their individual certificates through Co-WIN Portal, Aarogya Setu, Digilocker or the UMANG Application," he said.
ALSO READ
Jharkhand polls: Amit Shah to release BJP manifesto on Sunday, address 3 rallies
Jayant Patil claims BJP used irrigation 'scam' to blackmail Ajit Pawar
BJP to elect its legislature party leader in J-K Assembly on Sunday
Four workers killed after being hit by train near Shoranur Station in Kerala
Anees Ahmed back to Congress after failing to register his candidacy for polls
Also Read: Now ask Alexa to find nearest Covid vaccine centre
The Indian Council of Medical Research (ICMR) in partnership with the Serum Institute of India (SII) had conducted phase II/III bridging studies of Covishield from August 2020. Phase III efficacy clinical trials for Covaxin were conducted by Bharat Biotech International Limited (BBIL) from November 2020.
The ministry said it was decided that vaccination certificates may be issued to such participants who were administered the vaccines during these trials after the trials were unblinded.
The ICMR was designated as the nodal agency for the collection of vaccination data for such participants by the ministry.
"The ICMR had provided the data for 11,349 such persons to the MoHFW. Digital vaccination certificates have now been issued through Co-WIN to such persons who participated in these studies/trials of Covishield and Covaxin," the statement said.
This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever.